Stockreport

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Aut...

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Months to November 22, 2026 -- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SV [Read more]